In February, the drugmakers reported that the vaccine candidate was effective in adults after a three-dose series. Pfizer and Valneva also tested the vaccine in children ages 5-17, finding the vaccine was more immunogenic in adult trial participants, according to an April 26 news release.
The drugmakers will include pediatric participants in their phase 3 trial, which is expected to begin in the third quarter of 2022.
The Iowa Senate has passed a bill that would set new requirements for pharmacy benefit managers that lawmakers say will…
Mark Cuban Cost Plus Drug Co. has secured another partnership targeting the specialty pharmaceutical market, according to an April 28…
At Children’s Hospital of Philadelphia, an 11-year-old girl with severe beta thalassamia, became the first pediatric patient to receive Zyntelgo,…
Comments are closed.
